标签归档：infliximab

LEESGGGLVQPGGSMK

发表于由

LEESGGGLVQPGGSMK;

LEESGGGLVQPGGSMK，一种蛋白水解肽，是 Infliximab 的一种成分，可用于 Infliximab 的定量分析。Infliximab 是一种与 TNF-α 特异性结合的嵌合单克隆 IgG1 抗体。

LEESGGGLVQPGGSMKamp;;

LEESGGGLVQPGGSMK Chemical Structure

CAS No. : 2096980-79-7

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

LEESGGGLVQPGGSMK 的其他形式现货产品:

LEESGGGLVQPGGSMK acetate

生物活性

LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α[1].

体外研究
(In Vitro)

The anti-TNF antibodies blocking the action of TNF alpha revolutionized therapy of TNF-related diseases such as Inflammatory Bowel Disease, lupus, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis. By neutralizing TNF activity, anti-TNF antibodies promote mucosal healing and induce long-term remissions in vivo. The main anti-TNF antibodies that are currently authorized encompass Infliximab, Etanercept, Adalimumab, Certolizumab and Golimumab[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1545.71

Formula

C64H108N18O24S
CAS 号

2096980-79-7
Sequence

Leu-Glu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Met-Lys
Sequence Shortening

LEESGGGLVQPGGSMK
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Dorothée LEBERT, et al. A method for quantifying therapeutic antibodies. EP3371592A1.

LEESGGGLVQPGGSMK TFA

发表于由

LEESGGGLVQPGGSMK TFA;

LEESGGGLVQPGGSMK TFA，一种蛋白水解肽，是 Infliximab 的一种成分，可用于 Infliximab 的定量分析。Infliximab 是一种与 TNF-α 特异性结合的嵌合单克隆 IgG1 抗体。

LEESGGGLVQPGGSMK TFAamp;;

LEESGGGLVQPGGSMK TFA Chemical Structure

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

LEESGGGLVQPGGSMK TFA 的其他形式现货产品:

LEESGGGLVQPGGSMK acetate

生物活性

LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α[1].

体外研究
(In Vitro)

The anti-TNF antibodies blocking the action of TNF alpha revolutionized therapy of TNF-related diseases such as Inflammatory Bowel Disease, lupus, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis. By neutralizing TNF activity, anti-TNF antibodies promote mucosal healing and induce long-term remissions in vivo. The main anti-TNF antibodies that are currently authorized encompass Infliximab, Etanercept, Adalimumab, Certolizumab and Golimumab[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1659.73

Formula

C66H109F3N18O26S
Sequence Shortening

LEESGGGLVQPGGSMK
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Dorothée LEBERT, et al. A method for quantifying therapeutic antibodies. EP3371592A1.

Infliximab(Synonyms: Avakine CT-P13)

发表于由

Infliximab;(Synonyms: Avakine; CT-P13) 纯度: 90.30%

Infliximab (Avakine) 是一种与 TNF-α 特异性结合的嵌合单克隆 IgG1 抗体。Infliximab 可阻止 TNF-α 与 TNF-α 受体 1 (TNFR1) 和 TNFR2 的相互作用。Infliximab 可用于自身免疫，慢性炎症性疾病和糖尿病神经病变的研究。

Infliximabamp;;(Synonyms: Avakine; CT-P13)

Infliximab Chemical Structure

CAS No. : 170277-31-3

规格 价格 是否有货 数量
1 mg ￥1200 In-stock
5 mg ￥3000 In-stock
25 mg ￥7500 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research[1][2].

IC50 Target[1]

TNF-α

;

体外研究
(In Vitro)

TNF-α-treated adipocytes shows a significant 64% decrease in insulin-stimulated glucose uptake, whereas Infliximab (10 ng/mL) reverses TNF-α actions by significantly improving glucose incorporation in 3T3L1 adipocytes. Infliximab restores phosphorylation of substrate-2 and AKT by attenuating protein-tyrosine phosphatase 1B (PTP1B) activation. Infliximab ameliorates TNF-α-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

A single injection of Infliximab (10 μg/g in 100 μl saline/dose ip) in diabetic TNF-α+/+) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 weeks. The increased TNF-α mRNA expression in diabetic dorsal root ganglion is also attenuated by Infliximab[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

CAS 号

170277-31-3
中文名称

英夫利昔单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Lucia A Méndez-García, et al. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol. 2018 Nov;88(5):e12716.

    [2]. Isamu Yamakawa, et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52.